Highest-materiality recent filing
Total revenue $24.3M (+8% YoY); software $14.6M (+9%), services $9.7M (+8%). Gross margin improved to 66% from 59%.
Simulations Plus Q1 revenue down 3% to $18.4M; adjusted EPS falls to $0.13
Revenue $18.4M (-3% YoY); software $8.9M (-17%), services $9.5M (+16%).
Simulations Plus Q4 revenue down 6% to $17.5M, posts net loss; reaffirms FY2026 guidance
Q4 total revenue $17.5M (-6% YoY); software $9.0M (-9%); services $8.4M (-3%).
Simulations Plus provides preliminary FY2025 revenue of $79.1M and FY2026 guidance of $79-82M
Preliminary FY2025 revenue $79.1M (+13% YoY); adjusted diluted EPS guidance $1.03-$1.10 for FY2026.
Simulations Plus dismisses Grant Thornton, reappoints RSJ as auditor citing 10-Q timeline concerns
Dismissed Grant Thornton LLP on July 9, 2025; re-hired Rose, Snyder & Jacobs LLC for FY2025.
Simulations Plus Q3 net loss $67.3M on $77.2M impairment; adjusted EPS $0.45 tops year-ago $0.27
Total revenue $20.4M (+10% YoY); software $12.6M (+6%), services $7.7M (+17%).
Simulations Plus pre-announces Q3 revenue $19-20M; lowers FY2025 guidance to $76-80M
Preliminary Q3 FY2025 revenue expected between $19M and $20M.
Simulations Plus Q3 FY2025 revenue prelim $19-20M; full-year guidance cut to $76-80M
Preliminary Q3 FY2025 revenue expected $19-20M, subject to final adjustment.
John DiBella appointed Chief Revenue Officer; Daniel Szot departs at end of fiscal Q3 for other opportunities.
Erik Guffrey , currently Chief Technology Officer, Adaptive Learning & Insights and Medical Communications Products, assumes the new role of Co-Chief Product and Technology Officer.
Dr. Jonathan Chauvin , currently Business Unit Co-President, Clinical Pharmacology & Pharmacometric Solutions, assumes the new role of Co-Chief Product and Technology Officer.
Josh Fohey , currently Senior Vice President, Operations, assumes the new role of Chief Operating Officer.
On May 30, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Simulations Plus, Inc. (the “Company”) appointed John DiBella as Chief Revenue Officer of the Company, effective immediately.
Steven Chang , currently Business Unit President, Quantitative Systems Pharmacology Solutions, assumes the new role of Global Head of Strategic Alliances.
Jill Fiedler-Kelly , currently Business Unit Co-President, Clinical Pharmacology & Pharmacometric Solutions, assumes the new role of Interim President, Services Solutions.
Will Frederick , currently Chief Financial Officer and Chief Operating Officer, assumes the new role of Executive Vice President and Chief Financial Officer.
On the Effective Date, the Company and Daniel Szot, the Company’s Chief Revenue Officer, mutually agreed to Mr. Szot’s separation from the Company, to take effect at the end of the third fiscal quarter which allows for smooth transition as Mr. Szot seeks to pursue other opportunities.
Max materiality 0.80 · Median 0.68 · Most common event earnings